Price
No data yet.
Social Signal Score
Revenue
$620.44MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Christian Behrenbruch
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,152
- Beta
- 0.60
- Country
- AU
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 4.25
Financials
Revenue
$620.44M+318074.6%Net Income
$-7.25M-579.6%EBITDA
$28.92M+1751.8%Free Cash Flow
$-92.60M-6565056.7%EPS (diluted)
$-0.02-279.8%Shares Outstanding (diluted)
338.78M+164.7%Operating Expenses
$317.60MCash & Debt
$212.53MReturn of Capital
$0.00Revenue by Segment (annual)
$40.76MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.21B | $-10.69M | $-0.03 |
| 2024 | $783.21M | $49.92M | $0.15 |
| 2023 | $502.55M | $5.21M | $0.02 |
| 2022 | $160.10M | $-104.08M | $-0.34 |
| 2021 | $7.60M | $-80.51M | $-0.29 |
| 2020 | $5.21M | $-44.89M | $-0.17 |
| 2019 | $3.48M | $-27.87M | $-0.12 |
| 2018 | $195.1K | $-13.83M | $-0.07 |
| 2017 | $0.00 | $-6.38M | $-0.05 |
| 2016 | $0.00 | $-44.0K | $-0.00 |
| 2015 | $0.00 | $-132.0K | $-0.00 |
| 2000 | $0.00 | $-497.0K | $-0.01 |
| 1999 | $0.00 | $-289.0K | $-0.01 |
Valuation
TLXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
110Social Signal Score
Mentions (2)
- Newsmarketbeat.com·5h ago·Neutral
Telix Pharmaceuticals H1 Earnings Call Highlights Telix Pharmaceuticals NASDAQ: TLX reported first-half 2026 revenue of $477 million, up 22% from the prior-year period, as demand for its precision medicine imaging products continued to grow. The company said EBITDA increased 146% year over year to $52 million, while net profit after tax rose to $38 million.
View source ↗ - Newsglobenewswire.com·5h ago·Positive
Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline MELBOURNE, Australia and INDIANAPOLIS, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its financial results for the period ended June 30, 2026.
View source ↗
Earnings
Thu, Aug 20(today)
Consensus estimate $0.04 per share
Typical surprise -69.2% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Feb 19$-0.01 vs $0.03miss
- Wed, Aug 20$-0.01 vs $0.13miss
- Thu, Feb 20$0.11 vs $0.09beat
- Thu, Aug 22$0.06 vs $0.09miss
- Thu, Feb 22$0.04 vs $0.05miss
- Wed, Aug 23$-0.03 vs $0.04miss
Estimates and results for TLX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by TLX officers and directors.
- Bought
- $997k
- Sold
- —
2 trades
0 trades
- Behrenbruch Christianbought
- Behrenbruch Christianbought
45 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.